Asia-Pacific life and health (L&H) reinsurance is moving into sharper focus, with capacity providers leaning on the region for diversified, long-duration growth, Aon’s January 2026 renewal report said.
Against a softening P&C reinsurance environment, the report described APAC L&H in 2025 as steadily expanding, with ample capacity and a more deliberate use of reinsurance as a balance-sheet and risk-management tool.
On the demand side, primary life and health insurers are ceding more business as tighter risk-based capital regimes across markets such as Hong Kong, Korea and Japan steer buyers toward structured reinsurance, longevity and lapse solutions, and capital relief transactions.
Underlying customer growth also remains strong across the region, with rising population wealth and high medical inflation driving double-digit gross premium growth in many markets. In India, healthcare costs were projected to rise 13% in 2025, while health gross direct premiums climbed 52% year-on-year to ₹115.4bn in November.
Post-pandemic awareness of mortality, morbidity and income-protection gaps is still supporting demand for both individual and group protection, particularly in emerging markets.
At the same time, supply-side competition is intensifying. Global and regional reinsurers, third-party capital providers and private-equity-backed platforms are all targeting Asian life and health risks, attracted by long-term growth prospects.
Recent sidecar and partnership structures focused on Asian life and annuity portfolios point to deepening investor appetite, including Fortitude Re and Carlyle’s FCA Re sidecar, launched in October 2025 with more than $700m in deployable capital.
Separately, policy support is also building. China’s NFRA recently issued guidance encouraging domestic insurers to issue sidecar insurance-linked securities (ILS) in Hong Kong, widening access to catastrophe risk-transfer tools. Hong Kong’s Pilot ILS Grant Scheme, which has supported about HK$6.2bn of issuance as of April 2025, has been extended to 2028.
In renewal terms, traditional L&H reinsurance conditions are broadly stable to mildly cedant-favourable, with healthy overall appetite and capacity, though selectivity persists in long-term critical illness and medical expense covers where product design, medical-cost escalation and regulatory constraints make support harder to secure.
Even so, renewals have generally delivered satisfactory outcomes for cedants, with solid capacity for core lines and a continued emphasis on long-term partnerships. The strongest growth runway for traditional reinsurance sits in high-growth markets such as India and Southeast Asia, particularly across mortality, health and critical illness products.
Outside life and health, global speciality reinsurance renewals were generally stable to improving at 1/1, supported by benign losses, earlier engagement and ample capacity, though execution differed by line.
Aviation saw firmer momentum after heavier 2025 loss activity, including American Airlines, Air India and UPS losses, alongside greater certainty on Russia/Ukraine/Belarus claims following a June 11 UK court outcome. Retentions held, conditions tightened, and minimum rate-on-line levels on global catastrophe covers imposed over the past three years largely remained in place.
In marine and energy, reinsurers engaged earlier, but quotes and firm order terms largely stalled until the week before Christmas; once agreed, placements moved quickly and were signed earlier than in prior years. Entry and exit points were broadly stable, and buyers generally did not use savings to buy down attachment points.
Credit and surety renewals also recorded rate reductions at 1/1, except U.S. surety, where outcomes diverged based on exposure growth, portfolio mix and ceded performance.
